There are 15,360 results relating to "Medicin Viagra-m"
Order by
|
Official Report
Meeting date:
26 September 2019
Public Petitions Committee 26 September 2019
I have often heard about that happening. I have a niece whose medicine is brought in from Germany, so I know something about that.
Official Report
Meeting date:
8 October 2019
Meeting of the Parliament 08 October 2019
We have set up a Scottish medicines shortage response group, which will review evidence and intelligence and recommend action on such issues, should they emerge.
Official Report
Meeting date:
26 September 2017
Meeting of the Parliament 26 September 2017
I bear in mind the Scottish Government’s recent action to improve access to careers in medicine, particularly the establishment of the new graduate school of medicine, which will help to embed students within a primary care training pathway and facilitate their placements in remote and rural regions.
Last updated:
23 May 2023
WMMB_summaryofresponses
Bain, C.G., Bonn, A., Stoneman, R., Chapman, S., Coupar, A., Evans, M., Gearey, B., Howat, M., Joosten, H., Keenleyside, C., Labadz, J., Lindsay, R., Littlewood, N., Lunt, P., Miller, C.J., Moxey, A., Orr, H., Reed, M., Smith, P., Swales, V., Thompson, D.B.A., Thompson, P.S., ...
Questions and Answers
Date answered:
24 April 2012
S4W-06389
NHS boards are expected to maintain an overview of the effectiveness of their local arrangements for the introduction of new medicines, including NHS board decisions on SMC accepted medicines and management of Individual Patient Treatment Requests (IPTRs) for medicines not rec...
Questions and Answers
Date answered:
6 March 2014
S4W-19926
To ask the Scottish Government what progress the Scottish Medicines Consortium is making on establishing a value-based assessment of medicines for the treatment of long-term conditions, and whether it plans to develop this approach further.
Questions and Answers
Date answered:
4 September 2012
S4W-09124
Information on the “off-licence” use of medicines broken down by age group and type of use is not held centrally.
Last updated:
9 December 2019
Disclosure (Scotland) Bill as Introduced
Landmines 69 An offence under section 2 of the Landmines Act 1998 (prohibited conduct). Medicines 35 70 An offence under section 67(2) or (3) of the Medicines Act 1968 (offences under Part 3). 71 An offence under any of the following provisions of the Human Medicines Regulations 2012— 72 Disclosure (Scotland) Bill Schedule 2—List B offences Part 2—Statutory offences (a) regulation 34(1) (offences: breach of regulations and false information and defence concerning starting materials), (b) regulation 255(1)(a), (b), (c) or (d) (offences relating to dealings with medicinal products). 5 Mental health 72 An offence under section 318 of the Mental Health (Care and Treatment) (Scotland) Act 2003 (false statements).
Official Report
Meeting date:
30 April 2014
Meeting of the Parliament 30 April 2014
(S4O-03149) Tamiflu is not a vaccine. It is an antiviral medicine for the treatment and post-exposure prevention of influenza.
Last updated:
29 August 2023
JSP2018to2019_Final
Accordingly, the Parliament resolved—That the Parliament calls on the Scottish Government, as a matter of urgency, to bring NHS National Services Scotland, the Scottish Medicines Consortium and the relevant pharmaceutical companies together to deliver access to the life-prolonging medicines, Perjeta and Orkambi, for patients in Scotland who need them; notes the commitment that was made by the Scottish Government in December 2016, following the Review of Access to New Medicines (the Montgomery Review), to improve ways of negotiating with drug companies on the cost of medicines; calls for a new system of negotiation to be implemented now; welcomes the introduction of a new ultra-orphan pathway within the Scottish Medicines Consortium process that will make available, with ongoing evaluation for at least three years, medicines for the rarest conditions; notes the roll- out of the Peer Approved Clinical System in June 2018, replacing individual patient treatment requests, which allows clinicians to seek medicines for their patients that are not currently accepted for routine use by the NHS in Scotland, and which makes clear that the cost of the medicine must not be part of the decision-making process; further notes the commitment of the Scottish Government to continue to use all Pharmaceutical Price Regulation Scheme rebate funding to support access to new medicines; welcomes the commitment of the Association of the British Pharmaceutical Industry for its members to provide Scotland with the same discounts offered elsewhere in the UK for accessing medicines; believes that pharmaceutical companies should offer NHS Scotland fair prices and should properly engage with health technology assessments in order to demonstrate the clinical effectiveness of their medicines, and further calls on the Scottish Government to remove barriers to make access to new drugs easier, including the reform of the Patient Access Scheme Assessment Group. 5.
